Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT phase 3 trial of tirzepatide in heart failure with preserved ejection fraction and obesity
MOH_2021-09-06_010124Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing Tirzepatide with Placebo (2 arms). Started May 2021; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on MOH_2021-09-06_010124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-06_010124.